Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Filings indexed 700 across all filing types
Latest filing 2020-11-24 Director's Dealing
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2020-11-24 English
NEW ENTERPRISE ASSOCIATES 14, L.P. -- MERSANA THERAPEUTICS. 13DA4
Major Shareholding Notification
2020-11-19 English
4
Director's Dealing
2020-11-12 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-09 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2020, by Mersana Therapeutics, Inc. It announces the release of a press release regarding financial results for the second quarter ended September 30, 2020. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished and not filed, indicating this is an announcement of financial results rather than the full earnings release itself. The document length is 3787 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER) announcement, as it contains key highlights of quarterly financial results but not the full detailed report or financial statements.
2020-11-09 English
4
Director's Dealing
2020-10-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.